Skip to main content
SpringerLink
Log in

The potential of 4-aryl-6-morpholino-3(2H)-pyridazinone-2-arylpiperazinylacetamide as a new scaffold for SIRT2 inhibition: in silico approach guided by pharmacophore mapping and molecular docking

  • Original Research
  • Published:
Medicinal Chemistry Research Aims and scope Submit manuscript

Abstract

Numerous studies have demonstrated that the aberrant enzymatic activity of SIRTs has been linked to various diseases like diabetes, cancer, inflammation, cardiovascular diseases, neurodegenerative disorders and therefore, the modulation of SIRTs is of therapeutic importance. The pharmacological action of substituted pyridazinones has been broadly studied and has received much attention on account of especially their cardiovascular, anticancer, anti-inflammatory, and analgesic activity. From this point of view, we evaluated our in-house compounds bearing substituted pyridazinone skeleton for their in vitro inhibitory potency against SIRT2 and the results were supported both by the compatibility with the pharmacophore model previously developed for selective SIRT2 inhibitors and by the interaction fingerprints in hSIRT2 active site. The results revealed that 4-aryl-6-morpholino-3(2H)-pyridazinone functionalized amide scaffold showing 48% inhibition against SIRT2 may be considered as a starting point in the development of new type SIRT2 inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Du J, Jiang H, Lin H. Investigating the ADP-ribosyltransferase activity of Sirtuins with NAD Analogues and 32P-NAD. Biochemistry. 2009;48:2878–90. https://doi.org/10.1021/bi802093g.

    Article  CAS  PubMed  Google Scholar 

  2. Jiang H, Khan S, Wang Y, Charron G, He B, Sebastian C, et al. SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine. Nature. 2013;496:110–3. https://doi.org/10.1038/nature12038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 2011;334:806. https://doi.org/10.1126/science.1207861.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. Annu Rev Biochem 2006;75:435–65. https://doi.org/10.1146/annurev.biochem.74.082803.133500.

    Article  CAS  PubMed  Google Scholar 

  5. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The Human Sir2 Ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell. 2003;11:437–44. https://doi.org/10.1016/S1097-2765(03)00038-8.

    Article  CAS  PubMed  Google Scholar 

  6. Zhang L, Kim S, Ren X. The clinical significance of SIRT2 in malignancies: a tumor suppressor or an oncogene? Front Oncol. 2020;10:1721. https://doi.org/10.3389/fonc.2020.01721.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zhao Y, Wang L, Yang J, Zhang P, Ma K, Zhou J, et al. Anti-neoplastic activity of the cytosolic FoxO1 results from autophagic cell death. Autophagy. 2010;6:988–90. https://doi.org/10.4161/auto.6.7.13289.

    Article  PubMed  Google Scholar 

  8. Xu Y, Li F, Lv L, Li T, Zhou X, Deng C-X, et al. Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res. 2014;74:3630. https://doi.org/10.1158/0008-5472.CAN-13-3615.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhang H, Park S-H, Pantazides BG, Karpiuk O, Warren MD, Hardy CW, et al. SIRT2 directs the replication stress response through CDK9 deacetylation. Proc Natl Acad Sci USA. 2013;110:13546. https://doi.org/10.1073/pnas.1301463110.

  10. Beirowski B, Gustin J, Armour SM, Yamamoto H, Viader A, North BJ, et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci USA. 2011;108:E952. https://doi.org/10.1073/pnas.1104969108.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wang Y-P, Zhou L-S, Zhao Y-Z, Wang S-W, Chen L-L, Liu L-X, et al. Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. 2014;33:1304–20. https://doi.org/10.1002/embj.201387224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lagunas-Rangel FA. Current role of mammalian sirtuins in DNA repair. DNA Repair. 2019;80:85–92. https://doi.org/10.1016/j.dnarep.2019.06.009.

    Article  CAS  PubMed  Google Scholar 

  13. Ng F, Tang BL. Sirtuins’ modulation of autophagy. J Cell Physiol. 2013;228:2262–70. https://doi.org/10.1002/jcp.24399.

    Article  CAS  PubMed  Google Scholar 

  14. Seung Min J, Haigis MC. Sirtuins in cancer: a balancing act between genome stability and metabolism. Mol Cells. 2015;38:750–8. https://doi.org/10.14348/molcells.2015.0167.

    Article  CAS  Google Scholar 

  15. Carafa V, Rotili D, Forgione M, Cuomo F, Serretiello E, Hailu GS, et al. Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics. 2016;8:61. https://doi.org/10.1186/s13148-016-0224-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhang Y, Anoopkumar-Dukie S, Arora D, Davey AK. Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases. Eur J Pharmacol. 2020;867:172847. https://doi.org/10.1016/j.ejphar.2019.172847.

    Article  CAS  PubMed  Google Scholar 

  17. Jing H, Hu J, He B, Negrón Abril YL, Stupinski J, Weiser K, et al. A SIRT2-selective inhibitor Promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity. Cancer Cell. 2016;29:297–310. https://doi.org/10.1016/j.ccell.2016.02.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shah AA, Ito A, Nakata A, Yoshida M. Identification of a selective SIRT2 inhibitor and its anti-breast cancer activity. Biol Pharm Bull. 2016;39:1739–42. https://doi.org/10.1248/bpb.b16-00520.

    Article  CAS  PubMed  Google Scholar 

  19. Moniot S, Forgione M, Lucidi A, Hailu GS, Nebbioso A, Carafa V, et al. Development of 1,2,4-oxadiazoles as potent and selective inhibitors of the human deacetylase sirtuin 2: structure–activity relationship, x-ray crystal structure, and anticancer activity. J Med Chem. 2017;60:2344–60. https://doi.org/10.1021/acs.jmedchem.6b01609.

    Article  CAS  PubMed  Google Scholar 

  20. Rumpf T, Schiedel M, Karaman B, Roessler C, North BJ, Lehotzky A, et al. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat Commun. 2015;6:6263. https://doi.org/10.1038/ncomms7263.

    Article  CAS  PubMed  Google Scholar 

  21. Quinti L, Casale M, Moniot S, Pais Teresa F, Van Kanegan Michael J, Kaltenbach Linda S, et al. SIRT2- and NRF2-targeting thiazole-containing compound with therapeutic activity in huntington’s disease models. Cell Chem Biol. 2016;23:849–61. https://doi.org/10.1016/j.chembiol.2016.05.015.

    Article  CAS  PubMed  Google Scholar 

  22. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue α-Synuclein-mediated toxicity in models of parkinson’s disease. Science. 2007;317:516–9. https://doi.org/10.1126/science.1143780.

    Article  CAS  PubMed  Google Scholar 

  23. Taylor DM, Balabadra U, Xiang Z, Woodman B, Meade S, Amore A, et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem Biol. 2011;6:540–6. https://doi.org/10.1021/cb100376q.

    Article  CAS  PubMed  Google Scholar 

  24. Ai T, Wilson DJ, More SS, Xie J, Chen L. 5-((3-Amidobenzyl)oxy)nicotinamides as sirtuin 2 inhibitors. J Med Chem. 2016;59:2928–41. https://doi.org/10.1021/acs.jmedchem.5b01376.

    Article  CAS  PubMed  Google Scholar 

  25. Seifert T, Malo M, Kokkola T, Engen K, Fridén-Saxin M, Wallén EAA, et al. Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells. J Med Chem. 2014;57:9870–88. https://doi.org/10.1021/jm500930h.

    Article  CAS  PubMed  Google Scholar 

  26. Wang L, Li C, Chen W, Song C, Zhang X, Yang F, et al. Discovery of (5-phenylfuran-2-yl)methanamine derivatives as new human sirtuin 2 inhibitors. Molecules. 2019;24:2724. https://doi.org/10.3390/molecules24152724.

    Article  CAS  PubMed Central  Google Scholar 

  27. Radwan MO, Ciftci HI, Ali TFS, Koga R, Tateishi H, Nakata A, et al. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition. Bioorg Med Chem Lett. 2020;30:127458. https://doi.org/10.1016/j.bmcl.2020.127458.

    Article  CAS  PubMed  Google Scholar 

  28. Khalil NA, Ahmed EM, Zaher AF, El-Zoghbi MS, Sobh EA. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors. Eur J Med Chem. 2020;187:111926. https://doi.org/10.1016/j.ejmech.2019.111926.

    Article  CAS  PubMed  Google Scholar 

  29. Eren G, Bruno A, Guntekin-Ergun S, Cetin-Atalay R, Ozgencil F, Ozkan Y, et al. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors. J Mol Graph Model. 2019;89:60–73. https://doi.org/10.1016/j.jmgm.2019.02.014.

    Article  CAS  PubMed  Google Scholar 

  30. Yagci S, Gozelle M, Kaya SG, Ozkan Y, Aksel AB, Bakar-Ates F, et al. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT. Bioorg Med Chem. 2021;30:115961. https://doi.org/10.1016/j.bmc.2020.115961.

    Article  CAS  PubMed  Google Scholar 

  31. Akhtar W, Shaquiquzzaman M, Akhter M, Verma G, Khan MF, Alam MM. The therapeutic journey of pyridazinone. Eur J Med Chem. 2016;123:256–81. https://doi.org/10.1016/j.ejmech.2016.07.061.

    Article  CAS  PubMed  Google Scholar 

  32. Süküroglu M, Küpeli E, Banoglu E, Ünlü S, Yesilada E, Sahin MF. Synthesis and analgesic activity of some 4,6-disubstituted-3(2h)-pyridazinone derivatives. Arzneimittelforschung. 2006;56:337–45. https://doi.org/10.1055/s-0031-1296731.

    Article  PubMed  Google Scholar 

  33. Ochiai K, Takita S, Eiraku T, Kojima A, Iwase K, Kishi T, et al. Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure–activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem. 2012;20:1644–58. https://doi.org/10.1016/j.bmc.2012.01.033.

    Article  CAS  PubMed  Google Scholar 

  34. Abouzid K, Bekhit SA. Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity. Bioorg Med Chem. 2008;16:5547–56. https://doi.org/10.1016/j.bmc.2008.04.007.

    Article  CAS  PubMed  Google Scholar 

  35. Sharma D, Bansal R. Synthesis of 2-substituted-4-aryl-6-phenylpyridazin-3(2H)-ones as potential anti-inflammatory and analgesic agents with cardioprotective and ulcerogenic sparing effects. Med Chem Res. 2016;25:1574–89. https://doi.org/10.1007/s00044-016-1588-9.

    Article  CAS  Google Scholar 

  36. Asano T, Yamazaki H, Kasahara C, Kubota H, Kontani T, Harayama Y, et al. Identification, Synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP Kinase inhibitor. J Med Chem. 2012;55:7772–85. https://doi.org/10.1021/jm3008008.

    Article  CAS  PubMed  Google Scholar 

  37. Yue Q, Zhao Y, Hai L, Zhang T, Guo L, Wu Y. First synthesis of novel 3,3′-bipyridazine derivatives as new potent antihepatocellular carcinoma agents. Tetrahedron. 2015;71:7670–5. https://doi.org/10.1016/j.tet.2015.07.063.

    Article  CAS  Google Scholar 

  38. Zhou S, Liao H, He C, Dou Y, Jiang M, Ren L, et al. Design, synthesis and structure–activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents. Eur J Med Chem. 2014;83:581–93. https://doi.org/10.1016/j.ejmech.2014.06.068.

    Article  CAS  PubMed  Google Scholar 

  39. Csókás D, Zupkó I, Károlyi BI, Drahos L, Holczbauer T, Palló A, et al. Synthesis, spectroscopy, X-ray analysis and in vitro antiproliferative effect of ferrocenylmethylene-hydrazinylpyridazin-3(2H)-ones and related ferroceno[d]pyridazin-1(2H)-ones. J Organomet Chem. 2013;743:130–8. https://doi.org/10.1016/j.jorganchem.2013.06.040.

    Article  CAS  Google Scholar 

  40. Al-Tel TH. Design and synthesis of novel tetrahydro-2H-pyrano[3,2-c]pyridazin-3(6H)-one derivatives as potential anticancer agents. Eur J Med Chem. 2010;45:5724–31. https://doi.org/10.1016/j.ejmech.2010.09.029.

    Article  CAS  PubMed  Google Scholar 

  41. Zimmerman G, Soreq H. Termination and beyond: acetylcholinesterase as a modulator of synaptic transmission. Cell Tissue Res. 2006;326:655–69. https://doi.org/10.1007/s00441-006-0239-8.

    Article  CAS  PubMed  Google Scholar 

  42. Lin H, Fang H, Wang J, Meng Q, Dai X, Wu S, et al. Discovery of a novel 2,3,11,11a-tetrahydro-1H-pyrazino[1,2-b]isoquinoline-1,4(6H)-dione series promoting neurogenesis of human neural progenitor cells. Bioorg Med Chem Lett. 2015;25:3748–53. https://doi.org/10.1016/j.bmcl.2015.05.084.

    Article  CAS  PubMed  Google Scholar 

  43. Boukharsa Y, Meddah B, Tiendrebeogo RY, Ibrahimi A, Taoufik J, Cherrah Y, et al. Synthesis and antidepressant activity of 5-(benzo[b]furan-2-ylmethyl)-6-methylpyridazin-3(2H)-one derivatives. Med Chem Res. 2016;25:494–500. https://doi.org/10.1007/s00044-015-1490-x.

    Article  CAS  Google Scholar 

  44. Schiedel M, Rumpf T, Karaman B, Lehotzky A, Oláh J, Gerhardt S, et al. Aminothiazoles as potent and selective Sirt2 inhibitors: a structure–activity relationship study. J Med Chem. 2016;59:1599–612. https://doi.org/10.1021/acs.jmedchem.5b01517.

    Article  CAS  PubMed  Google Scholar 

  45. Fagbohun OF, Olawoye B, Ademakinwa AN, Oriyomi OV, Fagbohun OS, Fadare OA, et al. UHPLC/GC-TOF-MS metabolomics, MTT assay, and molecular docking studies reveal physostigmine as a new anticancer agent from the ethyl acetate and butanol fractions of Kigelia africana (Lam.) Benth. fruit extracts. Biomed Chromatogr. 2021;35:e4979. https://doi.org/10.1002/bmc.4979.

    Article  CAS  PubMed  Google Scholar 

  46. Fagbohun OF, Oriyomi OV, Adekola MB, Msagati TAM. Biochemical applications of Kigelia africana (Lam.) Benth. fruit extracts in diabetes mellitus. Comp Clin Path. 2020;29:1251–64. https://doi.org/10.1007/s00580-020-03179-9.

    Article  CAS  Google Scholar 

  47. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem. 2006;49:6177–96. https://doi.org/10.1021/jm051256o.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Prof. Mustafa Fethi SAHIN (Eastern Mediterranean University, Faculty of Pharmacy) for his supervisor’s contributions in design and synthesis of the in-house compounds.

Author information

Author notes

  1. These authors contributed equally: Murat Kadir Sukuroglu, Mahmut Gozelle

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330, Ankara, Turkey

    Murat Kadir Sukuroglu, Mahmut Gozelle & Gokcen Eren

  2. Department of Biochemistry, Faculty of Pharmacy, Gazi University, 06330, Ankara, Turkey

    Yesim Ozkan

Authors
  1. Murat Kadir Sukuroglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahmut Gozelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yesim Ozkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gokcen Eren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Murat Kadir Sukuroglu.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sukuroglu, M.K., Gozelle, M., Ozkan, Y. et al. The potential of 4-aryl-6-morpholino-3(2H)-pyridazinone-2-arylpiperazinylacetamide as a new scaffold for SIRT2 inhibition: in silico approach guided by pharmacophore mapping and molecular docking. Med Chem Res 30, 1915–1924 (2021). https://doi.org/10.1007/s00044-021-02782-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00044-021-02782-x

Keywords

Search

Navigation